CD274 and hepatocellular carcinoma: A phase 2 single-arm study (START-FIT, NCT03817736) evaluated sequential TACE and SBRT followed by avelumab (anti-PDL1) in locally advanced HCC, with the rate of amenable to curative treatment as the primary endpoint.